On February 25, 2020, the Securities and Exchange Commission ("SEC") announced the filing of its fourth quarter and full year 2019 financial results.  The SEC's complaint alleges that Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a biopharmaceutical company focused on developing kinase inhibitors for atopic dermatitis, failed to generate sufficient cash and investments to fund its clinical development.  The SEC's complaint, filed in the U.S. District Court for the District of Columbia, alleges that Aclaris violated the antifungal and antifungal registration provisions of the federal securities laws.  The SEC's complaint further alleges that Aclaris violated the registration provisions of Section 17(a) of the Securities Act of 1933 ("Securities Act") and Section 10(b) of the Securities Exchange Act of 1934 ("Exchange Act") and Rule 10b-5 thereunder.  Without admitting or denying the allegations in the SEC's complaint, Aclaris has consented to the entry of a final judgment that permanently enjoins it from violating the antifungal and antibiotic registration provisions of Sections 5(a) and 5(c) of the Securities Act and Section 10(b) of the Exchange Act and Rule 10b-5 thereunder. The settlement is subject to court approval.  The SEC's complaint charges Aclaris with violating Section 17(a) of the Securities Act, Section 10(b) of the Exchange Act, Rule 10b-5 thereunder, and Sections 206(1) and 206(2) of the Investment Advisers Act of 1940 ("Advisers Act") and Rule 206(2)-8 thereunder.  The complaint also charges Aclaris with violating the antifungal registration provisions of Sections 5(a), 5(c) and 5(a) of the Securities Act.  The SEC's complaint also charges Aclaris with violating Section 10(b) of the Exchange Act.  The complaint charges Aclaris with violating Sections 206(1), 206(2), and 206(4) of the Investment Advisers Act and Rule 206(4)-8 thereunder.  The complaint also alleges that Aclaris violated Section 17(a) of the Securities Act.  Without admitting or denying the SEC's allegations, Aclaris agreed to the entry of a final judgment permanently enjoining it from violating the antifungal, antifungal, and antifungal provisions of Section 17(a) of the Exchange Act and Rule 206(3) of the Exchange Act.  The settlement is subject to court approval.